Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4725800 | 0.77 | CHEK1 (0.40) | CHEK1AURKA | |
| SCHEMBL1735020 | 0.72 | CHEK1 (0.50) | CHEK1AURKA | |
| SCHEMBL1128452 | 0.72 | CHEK1 (0.47) | CHEK1AURKA | |
| SCHEMBL1128551 | 0.71 | CHEK1 (0.43) | CHEK1AURKA | |
| SCHEMBL1128852 | 0.70 | CHEK1 (0.40) | CHEK1AURKA | |
| Methane SCHEMBL10423240 | 0.70 | CHEK1 (0.46) | CHEK1AURKA | |
| SCHEMBL1129156 | 0.68 | AURKA (0.38) | CHEK1AURKA | |
| SCHEMBL9918632 | 0.68 | CCR4 (0.50) | CHEK1AURKA | |
| SCHEMBL473315 | 0.67 | CHEK1 (0.43) | CHEK1AURKA | |
| SCHEMBL311873 | 0.67 | CHEK1 (0.52) | CHEK1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2148880-B1 | P70 S6 KINASE INHIBITORS | LILLY CO ELI (US) | 2014-05-28 | — | — | EP | disclosed |
| US-20120071490-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-03-22 | — | — | US | disclosed |
| US-8093383-B2 | P70 S6 kinase inhibitors | ELI LILLY AND COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| US-20090163714-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163714-A1 | P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, RPS6KA2 | CHEK1 521/4885AURKA 906/4885 |
| US-20120071490-A1 | P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, RPS6KA2 | CHEK1 521/4885AURKA 906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.